Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors

Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established preclinical taxane-platin-chemoresistance models and identified a 35-gene resistance signature, which was associated with poor recurrence-fr...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Maithili P. Dalvi, Lei Wang, Rui Zhong, Rahul K. Kollipara, Hyunsil Park, Juan Bayo, Paul Yenerall, Yunyun Zhou, Brenda C. Timmons, Jaime Rodriguez-Canales, Carmen Behrens, Barbara Mino, Pamela Villalobos, Edwin R. Parra, Milind Suraokar, Apar Pataer, Stephen G. Swisher, Neda Kalhor, Natarajan V. Bhanu, Benjamin A. Garcia, John V. Heymach, Kevin Coombes, Yang Xie, Luc Girard, Adi F. Gazdar, Ralf Kittler, Ignacio I. Wistuba, John D. Minna, Elisabeth D. Martinez
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2017-05-01
סדרה:	Cell Reports
נושאים:	Jumonji demethylases JIB-04 GSK-J4 drug resistance taxane-platin chemotherapy KDM demethylase inhibitors histone methylation histone demethylases lung cancer
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2211124717306071
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!